PURPOSE: ABT-888 inhibits poly(ADP-ribose) polymerase (PARP) and may enhance the efficacy of chemotherapy and radiation in CNS tumors. We studied the plasma and cerebrospinal fluid (CSF) pharmacokinetics (PK) of ABT-888 in a non-human primate (NHP) model that is highly predictive of human CSF penetration. METHODS: ABT-888, 5 mg/kg, was administered orally to three NHPs. Serial blood and CSF samples were obtained. Plasma and CSF concentrations of ABT-888 were measured using LC/MS/MS, and the resulting concentration versus time data were evaluated using non-compartmental and compartmental PK methods. RESULTS: The CSF penetration of ABT-888 was 57+/-7% (mean+/-SD). The peak ABT-888 concentration in the plasma was 0.62+/-0.18 microM. Plasma and CSF AUC0-infinity were 3.7+/-1.7 and 2.1+/-0.8 microM h. PARP inhibition in peripheral blood mononuclear cells was evident 2 h after ABT-888 administration. CONCLUSION: The CSF penetration of ABT-888 after oral administration was 57%. Plasma and CSF concentrations were in the range that has been shown to inhibit PARP activity in vivo in humans.
PURPOSE:ABT-888 inhibits poly(ADP-ribose) polymerase (PARP) and may enhance the efficacy of chemotherapy and radiation in CNS tumors. We studied the plasma and cerebrospinal fluid (CSF) pharmacokinetics (PK) of ABT-888 in a non-human primate (NHP) model that is highly predictive of human CSF penetration. METHODS:ABT-888, 5 mg/kg, was administered orally to three NHPs. Serial blood and CSF samples were obtained. Plasma and CSF concentrations of ABT-888 were measured using LC/MS/MS, and the resulting concentration versus time data were evaluated using non-compartmental and compartmental PK methods. RESULTS: The CSF penetration of ABT-888 was 57+/-7% (mean+/-SD). The peak ABT-888 concentration in the plasma was 0.62+/-0.18 microM. Plasma and CSF AUC0-infinity were 3.7+/-1.7 and 2.1+/-0.8 microM h. PARP inhibition in peripheral blood mononuclear cells was evident 2 h after ABT-888 administration. CONCLUSION: The CSF penetration of ABT-888 after oral administration was 57%. Plasma and CSF concentrations were in the range that has been shown to inhibit PARP activity in vivo in humans.
Authors: C A Delaney; L Z Wang; S Kyle; A W White; A H Calvert; N J Curtin; B W Durkacz; Z Hostomsky; D R Newell Journal: Clin Cancer Res Date: 2000-07 Impact factor: 12.531
Authors: M Shiobara; M Miyazaki; H Ito; A Togawa; N Nakajima; F Nomura; N Morinaga; M Noda Journal: J Gastroenterol Hepatol Date: 2001-03 Impact factor: 4.029
Authors: Xuesong Liu; Joann Palma; Robert Kinders; Yan Shi; Cherrie Donawho; Paul A Ellis; Luis E Rodriguez; Milagros Colon-Lopez; Mary Saltarelli; David LeBlond; C Thomas Lin; David J Frost; Yan Luo; Vincent L Giranda Journal: Anal Biochem Date: 2008-07-16 Impact factor: 3.365
Authors: Lucio Tentori; Carlo Leonetti; Marco Scarsella; Giulia D'Amati; Matteo Vergati; Ilaria Portarena; Weizheng Xu; Vincent Kalish; Gabriella Zupi; Jie Zhang; Grazia Graziani Journal: Clin Cancer Res Date: 2003-11-01 Impact factor: 12.531
Authors: Christopher R Calabrese; Robert Almassy; Stephanie Barton; Michael A Batey; A Hilary Calvert; Stacie Canan-Koch; Barbara W Durkacz; Zdenek Hostomsky; Robert A Kumpf; Suzanne Kyle; Jianke Li; Karen Maegley; David R Newell; Elena Notarianni; Ian J Stratford; Donald Skalitzky; Huw D Thomas; Lan-Zhen Wang; Stephen E Webber; Kaye J Williams; Nicola J Curtin Journal: J Natl Cancer Inst Date: 2004-01-07 Impact factor: 13.506
Authors: Patricia A Baxter; Jack M Su; Arzu Onar-Thomas; Catherine A Billups; Xiao-Nan Li; Tina Young Poussaint; Edward R Smith; Patrick Thompson; Adekunle Adesina; Pete Ansell; Vincent Giranda; Arnold Paulino; Lindsey Kilburn; Ibrahim Quaddoumi; Alberto Broniscer; Susan M Blaney; Ira J Dunkel; Maryam Fouladi Journal: Neuro Oncol Date: 2020-06-09 Impact factor: 12.300
Authors: Jack M Su; Patrick Thompson; Adekunle Adesina; Xiao-Nan Li; Lindsay Kilburn; Arzu Onar-Thomas; Mehmet Kocak; Brenda Chyla; Evelyn McKeegan; Katherine E Warren; Stewart Goldman; Ian F Pollack; Maryam Fouladi; Alice Chen; Vincent Giranda; James Boyett; Larry Kun; Susan M Blaney Journal: Neuro Oncol Date: 2014-06-07 Impact factor: 12.300
Authors: Dimitrios E Kouzoukas; Jennifer A Schreiber; Nuzhath F Tajuddin; Simon Kaja; Edward J Neafsey; Hee-Yong Kim; Michael A Collins Journal: Neurochem Int Date: 2019-06-25 Impact factor: 3.921
Authors: Sarah Reinhardt; Ming Zhao; Aleksander Mnatsakanyan; Linping Xu; Rebecca M Ricklis; Alice Chen; Judith E Karp; Michelle A Rudek Journal: J Pharm Biomed Anal Date: 2009-12-29 Impact factor: 3.935
Authors: Parker L Sulkowski; Christopher D Corso; Nathaniel D Robinson; Susan E Scanlon; Karin R Purshouse; Hanwen Bai; Yanfeng Liu; Ranjini K Sundaram; Denise C Hegan; Nathan R Fons; Gregory A Breuer; Yuanbin Song; Ketu Mishra-Gorur; Henk M De Feyter; Robin A de Graaf; Yulia V Surovtseva; Maureen Kachman; Stephanie Halene; Murat Günel; Peter M Glazer; Ranjit S Bindra Journal: Sci Transl Med Date: 2017-02-01 Impact factor: 19.319
Authors: Rutger K Balvers; Martine L M Lamfers; Jenneke J Kloezeman; Anne Kleijn; Lotte M E Berghauser Pont; Clemens M F Dirven; Sieger Leenstra Journal: J Transl Med Date: 2015-02-26 Impact factor: 5.531
Authors: Suzana M Anjos; Renaud Robert; Daniel Waller; Dong Lei Zhang; Haouaria Balghi; Heidi M Sampson; Fabiana Ciciriello; Pierre Lesimple; Graeme W Carlile; Julie Goepp; Jie Liao; Pasquale Ferraro; Romeo Phillipe; Françoise Dantzer; John W Hanrahan; David Y Thomas Journal: Front Pharmacol Date: 2012-09-12 Impact factor: 5.810
Authors: Imke H Bartelink; Brendan Prideaux; Gregor Krings; Lisa Wilmes; Pei Rong Evelyn Lee; Pan Bo; Byron Hann; Jean-Philippe Coppé; Diane Heditsian; Lamorna Swigart-Brown; Ella F Jones; Sergey Magnitsky; Ron J Keizer; Niels de Vries; Hilde Rosing; Nela Pawlowska; Scott Thomas; Mallika Dhawan; Rahul Aggarwal; Pamela N Munster; Laura J Esserman; Weiming Ruan; Alan H B Wu; Douglas Yee; Véronique Dartois; Radojka M Savic; Denise M Wolf; Laura van 't Veer Journal: Breast Cancer Res Date: 2017-09-11 Impact factor: 6.466